Welcome to QBiotics

An Australian naturally inspired life sciences company

Human Health
Animal Health
Investor Health

UPDATES


Share Offer 2018 – Offer extended by 4 days

10 December 2018

The Share Offer was scheduled to close today, 10 December 2018, at 5.00pm. The Board has decided to extend the Closing Date for Applications to 14 December 2018 at 5.00pm to allow share applications which are still in progress to be completed and included in the Offer.


Positive results announced with first in-human study of tigilanol tiglate in solid tumours

13 November 2018

QBiotics Group Ltd has received positive results from the first in-human Phase I/IIA clinical trial of its anticancer pharmaceutical tigilanol tiglate in patients with solid tumours. The study was conducted across four Australian hospitals.


Prospectus approved by ASIC and opening of QBiotics Group capital raise

5 November 2018

QBiotics Group Limited is pleased to announce that the company prospectus lodged on Friday 26 October 2018 with the Australian Securities and Investments Commission (ASIC) has passed the statutory seven day review period without requisitions or amendments required by ASIC.


QBiotics prepares for a new capital raise

29 October 2018

QBiotics Group Limited has lodged a board-approved prospectus with the Australian corporate regulator the Australian Securities and Investments Commission (ASIC) on 26 October 2018.


Completion of QBiotics USA veterinary anti-cancer trial in USA treating dogs with Mast Cell Tumours

2 October 2018

The USA veterinary pivotal clinical study of tigilanol tiglate completes the data package for FDA and EMA submission.


QBiotics signs supply, marketing and distribution agreement with Virbac for canine cancer treatment

9 August 2018

QBiotics Group has signed an agreement with Virbac, one of the largest dedicated animal health companies globally, to supply, market and distribute its canine anticancer pharmaceutical, tigilanol tiglate.